Nadine Attal (University Versailles Saint Quentin, Versailles, France) shared with us her expert opinion on the controversial topic of therapeutic cannabis for neuropathic pain.
Questions
1. What advantages does cannabis offer compared to current pharmacological treatments for neuropathic pain? (0:05)
2. What can we conclude about the clinical evidence to date? (0:41)
3. What have we learned about the safety and potential long-term effects of therapeutic cannabis for neuropathic pain? (2:22)
4. Which patients are most likely to benefit from cannabis for pain relief and in which patients is it contraindicated? (3:34)
5. This is a very controversial issue. What other pros and cons should be considered? (4:46)
Speaker disclosure: Nadine Attal has received honoraria from Pfizer, Lilly, Aptynix, Sanofi, MSD, Novartis, Grunenthal, Ipsen over the past 3 years outside participation in this interview.
Support: Interview and filming supported by Touch Medical Media.
Filmed at the 6th Congress of the European Academy of Neurology (EAN) and 1st EAN Virtual Congress, May 2020.
